Death receptor 5 agonistic antibody + salinomycin
Death receptor 5 agonistic antibody + salinomycin has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 18, 2024: “An antibiotic that mediates immune destruction of senescent cancer cells”.
1 paper studies it2 findingsUpdated
None of its findings points the other way.
- 1 lab in 2 countries
- Funders: Basic and Applied Basic Research Foundation of Guangdong Province and 7 more
- Animals1
What did studies of Death receptor 5 agonistic antibody + salinomycin find?
2Studies of Death receptor 5 agonistic antibody + salinomycin measured 2 outcomes; the most studied are senescent cell destruction (1 study) and senescent-cell death (1).
Senescent cell destruction
upin human cells1
1 study
Senescent cell destruction
upin human cells1
Death receptor 5 agonistic antibody + salinomycin induces senescent cell destruction in human cells.
“this drug combination provokes a potent natural killer (NK) and CD8+ T cell-mediated immune destruction of senescent cancer cells, mediated by the pyroptotic cytokine interleukin 18 (IL18).”
Cellssenescent cancer cells
An antibiotic that mediates immune destruction of senescent cancer cells
Proceedings of the National Academy of Sciences of the United States of America
Senescent-cell death
upin human cells1
1 study
Senescent-cell death
upin human cells1
Death receptor 5 agonistic antibody + salinomycin induces senescent-cell death in human cells.
“We show that a combination of a death receptor 5 (DR5) agonistic antibody and salinomycin is a robust senolytic cocktail.”
Cellssenescent cancer cells
An antibiotic that mediates immune destruction of senescent cancer cells
Proceedings of the National Academy of Sciences of the United States of America